**8. Patient monitoring after completeness of the MDR-TB treatment [24]**

For assessment of the MDR-TB relapse rate, direct AFB-smear examinations and cultures are performed and assessed every 3 months in the first 6-month completeness of treatment and then every 6 months for 18 months. Chest radiological examinations are preformed when indicated.


**Table 3.** Classification of treatment outcomes [24]

standardized treatment is recommended yet. Types of patients with MDR-TB, patient moni‐ toring during MDR-TB treatment and assessment of sputum conversion, and classification of

**New case** patient who does not take any anti-TB drugs before or take any anti-TB drugs less than 1 month

**Relapse case** patient who cured of MDR-TB in the past and present or pre-treatment of relapse-MDR-TB DST

duration and the DST results show resistance to at least rifampicin and isoniazid

results reveal MDR-TB

patient who continuously interrupts the TB treatment more than 2 months and the DST results before treatment interruption demonstrates MDR-TB

patient' s AFB examinations show positive results at the end of the fifth month and the DST results at the end of the second or fifth month reveal MDR-TB

patient who treated with the retreatment regimen (2 months of streptomycin, rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by 1 month of rifampicin, isoniazid, pyrazinamide, and ethambutol , and then followed by 5 months of isoniazid, pyrazinamide, and ethambutol for relapse cases) and the DST results at the end of third or fifth month demonstrate MDR-TB

patient who is referred from one setting to the other setting for further diagnosis, treatment, and management, transferred setting must report the outcome of treatment to the referred setting (first setting) for discharge registration as " transfer in "

other patients who cannot be registered as the above 6 patient-registration types including patients who treated with empirical MDR-TB treatment regimen at the non-NTP settings (not registered as the above 6 patient-registration types)

> Results of 2 consecutively direct-AFB-smear negative and culture negative with 30-day intervals will indicate sputum conversion. Mostly, patients with sputum conversion will converse the positive to the negative results within the first 6 month of treatment duration.

**Patient monitoring during MDR-TB treatment Assessment of sputum conversion**

**Table 2.** Patient monitoring during MDR-TB treatment and Assessment of sputum conversion [24]

**8. Patient monitoring after completeness of the MDR-TB treatment [24]**

For assessment of the MDR-TB relapse rate, direct AFB-smear examinations and cultures are performed and assessed every 3 months in the first 6-month completeness of treatment and

treatment outcomes are shown in the Table 1, 2, and 3, respectively [24].

**Type Description**

252 Tuberculosis - Current Issues in Diagnosis and Management

**After default MDR-TB**

**After failure of the first- TB treatment**

> **After failure of retreatment**

> > **Transfer in**

**Other**

**Table 1.** Registration of the patients with MDR-TB [24]

Direct AFB-smear examinations and cultures will be performed at month : 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, , 14, 16, 18, and 20.

Chest radiological examinations will be performed at month : 0, 3, 6, 12, and 18.
